NattoPharma has since its startup in 2004 been a leading supplier of products based on Vitamin K2 in the form of menaquinone-7, marketed under the brand MenaQ7®. The MenaQ7® products are all based on scientific data. So far, 20 clinical studies all together show the benefits from MenaQ® on bone and cardiovascular health. MenaQ® is today manufactured both based on organic synthesis and through a fermentation process.
Project Fønix will through the collaboration with SINTEF and other partners, will give a crucial contribution to the research and development processes in NattoPharma. This will secure our ability to deliver new and competitive products to the global food and nutraceutical markets.